Results 71 to 80 of about 5,721 (196)
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias +2 more
wiley +1 more source
Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer
, 2018 Flavia Cochera,* Daniel Dinca,* Diana Aurora Bordejevic, Ioana Mihaela Citu, Adelina Marioara Mavrea, Minodora Andor, Mihai Trofenciuc, Mirela Cleopatra Tomescu Cardiology Department, “Victor Babes” University of Medicine and Pharmacy ...
Tomescu MC +7 more
core
Nitric oxide mechanisms of nebivolol
, 2009 β-blockers are among the most widely used drugs in the prevention and treatment of cardiovascular disease, although they are associated with increased peripheral resistance.
A. Maffei, LEMBO, Giuseppe
core +1 more source
Rhabdomyolysis in a patient taking nebivolol
, 2016 β Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β2 adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce ...
Ki Ryang Na +16 more
core +1 more source
EFFICACY AND TOLERABILITY OF NEBIVOLOL COMPARED WITH OTHER ANTIHYPERTENSIVE DRUGS: A META-ANALYSIS
Российский кардиологический журнал, 2011 Aim: Lowering BP to normal levels without quality of life deterioration is the most important means of reducing cardiovascular risk. Recent studies have challenged the position of beta-adrenoreceptor antagonists (beta-blockers) as first-line ...
L. M. Van Bortel +2 more
doaj
Journal of International Medical Research, 2020 Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation β blockers for hypertensive patients.
Jun-Ying Liu +6 more
doaj +1 more source
Nebivolol induces endothelium-dependent relaxations of canine coronary arteries
, 1991 Nebivolol is a new β1-antagonist that acutely reduces arterial blood pressure without depressing cardiac function. The present study was designed to determine the effect of nebivolol on coronary arteries. Rings of canine left anterior descending coronary
Gao, Y +4 more
core +1 more source
Antioxidant activity of nebivolol in the rat aorta
, 2004 The beta-blocker nebivolol is a racemic mixture Of D- and L-enantiomers that displays negative inotropic as well as direct vasorelaxant activity. In addition, it has been proposed that nebivolol exerts endothelium-protective effects caused by its ...
Mathy, Marie-Jeanne +3 more
core +1 more source
Discover ChemistryNebivolol, a beta-blocker commonly prescribed for the treatment of hypertension and heart failure, functions by decelerating heart rate and promoting vasodilation, thereby enhancing blood flow and reducing blood pressure.
Kurdo A. Abdullah +4 more
doaj +1 more source
Preventive effect of nebivolol on contrast-induced nephropathy in rats
, 2008 Background. Altered renal vasodilatation and oxidative stress are important mechanisms of contrast-induced nephropathy (CIN). The aim of the present study was to assess the effect of nebivolol, a beta blocker, on prevention of CIN.
Canoz, Ozlem +8 more
core +1 more source